AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

<p>IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that it has received a notice of allowance from the United States Patent and […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/aeon-biopharma-receives-notice-of-allowance-from-uspto-for-a-patent-covering-use-of-botulinum-toxins-to-treat-migraine-headache/">AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>